Board of Directors
Mr. KAM Yuen
Chairman and Director

Mr. Kam serves as our chairman and also chairman of the Nominating and Corporate Governance Committee. He is responsible for the strategic direction of CCBC. He is also the founder, chairman and chief executive officer of Golden Meditech Holdings Limited ("Golden Meditech") with over 20 years of experiences in the healthcare industry. Mr. Kam also serves as the Chairman and non-executive director of Life Corporation Limited, which is listed on the Australian Securities Exchange. He received his Bachelor of Arts degree in Japanese from the Beijing Second Foreign Languages Institute, the PRC.
Mr. KAM Yuen
Chairman and Director


Mr. Kam serves as our chairman and also chairman of the Nominating and Corporate Governance Committee. He is responsible for the strategic direction of CCBC. He is also the founder, chairman and chief executive officer of Golden Meditech Holdings Limited ("Golden Meditech") with over 20 years of experiences in the healthcare industry. Mr. Kam also serves as the Chairman and non-executive director of Life Corporation Limited, which is listed on the Australian Securities Exchange. He received his ... 
Ms. ZHENG Ting, Tina
Chief Executive Officer, Director, and Chief Executive Officer of Beijing Division

Ms. Zheng serves as our chief executive officer as well as the interim chief executive officer of our Beijing subsidiary. She has been in charge of our cord blood bank operations since 2003 and is responsible for the strategic development and overall management of CCBC. Aside from overseeing the overall operation of CCBC, she is also responsible for strategic developments, acquisition planning and negotiations, and formulating overall business strategy and various business initiatives of CCBC. She has more than ten years of experience in the fields of accounting, internal control, and corporate strategies and development in China's healthcare industry. Ms. Zheng had served as an executive director of Golden Meditech and had been in charge of its and its subsidiaries' financial and internal control systems since September 2001. She assumed a critical role in the initial public offering by Golden Meditech on the Growth Enterprise Market of the Hong Kong Stock Exchange in December 2001. Ms. Zheng became a non-executive director of Golden Meditech starting from August 2012. She played an important role in our acquisition of Nuoya ("Guangdong Province Cord Blood Bank") and investments in CordLife ("Life Corporation Limited and Cordlife Group Limited"). Prior to joining us, Ms. Zheng worked for Sino-reality Certified Public Accountants, an accounting firm in China, from 1997 to 2001. She received an EMBA degree from Renmin University of China.
Ms. ZHENG Ting, Tina
Chief Executive Officer, Director, and Chief Executive Officer of Beijing Division


Ms. Zheng serves as our chief executive officer as well as the interim chief executive officer of our Beijing subsidiary. She has been in charge of our cord blood bank operations since 2003 and is responsible for the strategic development and overall management of CCBC. Aside from overseeing the overall operation of CCBC, she is also responsible for strategic developments, acquisition planning and negotiations, and formulating overall business strategy and various business initiatives of CCBC. S... 
Mr. CHEN Bing Chuen, Albert
Chief Financial Officer and Director

Mr. Chen serves as our chief financial officer and a director. He is in charge of CCBC's finance-related matters, including accounting and budget planning. He is also involved in CCBC's corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies. For example, he played an important role in our acquisition of Nuoya ("Guangdong Province Cord Blood Bank") and investments in CordLife ("Life Corporation Limited and Cordlife Group Limited"). He had served as the corporate finance vice president of Golden Meditech since March 2005. Prior to joining Golden Meditech, Mr. Chen worked in a number of financial institutions, including SalomonSmithBarney, DBS Vickers Securities and UOB Kay Hian in Hong Kong. During his employment as an analyst in UOB Kay Hian from 2003 to March 2005, he was a senior analyst specializing in the pharmaceutical and healthcare industries and was ranked as one of the best analysts for small cap companies in the region in a poll conducted by Asia Money among brokers in 2003. Mr. Chen is a CFA charterholder. He received his bachelor's degree in commerce from Queen's University, Canada, School of Business in 1999 with a major in finance and accounting.
Mr. CHEN Bing Chuen, Albert
Chief Financial Officer and Director


Mr. Chen serves as our chief financial officer and a director. He is in charge of CCBC's finance-related matters, including accounting and budget planning. He is also involved in CCBC's corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies. For example, he played an important role in our acquisition of Nuoya ("Guangdong Province Cord Blood Bank") and investments in CordLife ("Life Corporation Limited and Cordlife Group Limited")... 
Mr. CHEN Mark D.
Independent Non-executive Director

Mark D. Chen, serves as one of our independent non-executive directors and also chairman of the Compensation Committee. Prior to the Business Combination on June 30, 2009, Mr. Chen was Pantheon’s chairman of the board, chief executive officer and president since its inception. He is currently Managing Partner of Pantheon Pacific Capital Management Ltd., a global private equity fund management and advisory company. Mr. Chen co-founded Easton Capital Investment Group, a New York based private equity investment firm in 1998 and has served as general partner of its various affiliated funds. He is currently a director and chairman of the Audit Committee of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI). Mr. Chen received a B.S. from the Shanghai Jiao Tong University in Shanghai, China, an M.S. from Pennsylvania State University and an M.B.A. from the Columbia Business School at Columbia University.
Mr. CHEN Mark D.
Independent Non-executive Director


Mark D. Chen, serves as one of our independent non-executive directors and also chairman of the Compensation Committee. Prior to the Business Combination on June 30, 2009, Mr. Chen was Pantheon’s chairman of the board, chief executive officer and president since its inception. He is currently Managing Partner of Pantheon Pacific Capital Management Ltd., a global private equity fund management and advisory company. Mr. Chen co-founded Easton Capital Investment Group, a New York based private equi... 
Dr. LU Ken
Independent Non-executive Director

Dr. Ken Lu has served as one of our independent non-executive directors since the Business Combination on June 30, 2009. Dr. Ken Lu is the chief executive officer of Seres Asset Management Limited ("Seres"), an investment management company focusing on the Asian equity markets. Prior to Seres, Dr. Lu founded and managed APAC Capital Advisors Limited, a Greater China investment specialist, from 2004 to early 2010. Dr. Lu's extensive capital market experience also includes research analyst roles at a number of leading investment banks, including JP Morgan and Credit Suisse (formerly Credit Suisse First Boston, or CSFB). He served as the Head of China Research at CSFB from October 2001 to May 2004. Dr. Lu also serves on the boards and Audit Committees of China Techfaith Wireless Communication Technology Limited and China Biologic Products Inc., both listed on the NASDAQ. Dr. Lu holds a Bachelor of Science degree from the Beijing University, a Master of Science from the Brigham Young University, and a Ph. D. degree in finance from the University of California, Los Angeles.
Dr. LU Ken
Independent Non-executive Director


Dr. Ken Lu has served as one of our independent non-executive directors since the Business Combination on June 30, 2009. Dr. Ken Lu is the chief executive officer of Seres Asset Management Limited ("Seres"), an investment management company focusing on the Asian equity markets. Prior to Seres, Dr. Lu founded and managed APAC Capital Advisors Limited, a Greater China investment specialist, from 2004 to early 2010. Dr. Lu's extensive capital market experience also includes research analyst roles a... 
Ms. WENG Jennifer J.
Independent Non-executive Director

Jennifer J. Weng, serves as one of our independent non-executive directors and also chairman of Audit Committee. Prior to the Business Combination on June 30, 2009, Ms. Weng was Pantheon’s chief financial officer and secretary since its inception. She currently serves as investment advisor to investment funds investing in private equity and real estate transactions in United States. Previously, she had held a variety of research and financial management positions with companies including Mizuho and Morgan Stanley in New York. Ms. Weng received a B.A. from Tongji University, China and an M.B.A. from Indiana University of Pennsylvania.
Ms. WENG Jennifer J.
Independent Non-executive Director


Jennifer J. Weng, serves as one of our independent non-executive directors and also chairman of Audit Committee. Prior to the Business Combination on June 30, 2009, Ms. Weng was Pantheon’s chief financial officer and secretary since its inception. She currently serves as investment advisor to investment funds investing in private equity and real estate transactions in United States. Previously, she had held a variety of research and financial management positions with companies including Mizuho ...